hotspot -WSS

hotspot

author：explore 2025-09-05 18:31:53 - browse：896

Pfizer plans to exit a major biotechnology industry trade association. Cindy Ord/Getty Images for Pfizer/BioNTech

WASHINGTON — Pfizer has decided to leave the Biotechnology Innovation Organization, according to two sources familiar with the planning.

The departure is a blow to BIO, which represents members ranging from small biotech startups to massive pharmaceutical companies. The group on Tuesday announced its new CEO, rare disease advocate and biotech executive John Crowley.

“The economic situation for the industry is difficult indeed and we of course are disappointed that any company would be forced to take a break from its BIO membership. We certainly hope that when economic conditions improve, we can welcome those companies back and welcome new members to join us as well, but it in no way affects our mission of protecting patients and medical innovation in the United States,” said BIO’s Chief Public Affairs and Marketing Officer Rich Masters. Masters said he wouldn’t comment on the status of any particular member.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： HIV vaccine remains elusive. Immunologists keep trying new ideas

entertainment

WSS

Gene therapy’s promise and the high cost of hope

Wearables generate powerful data but its not useful to doctors, yet

Bill would allow buprenorphine prescription for addiction via telehealth

The health care issue Democrats can’t solve: hospital reform

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Venture capitalist Bob Kocher on the state of digital health

focus

hotspot

entertainment

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

NVIDIA and Google execs on the future of AI and drug discovery

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Medical records are filled with copy

Key Senate panel to consider PBM, drug pricing reform package

Duchenne breakthrough therapy leaves behind pioneering families

How to convince healthy people to buy insurance

State Dept. review finds Biden bears some blame for Afghanistan failures

Wearables generate powerful data but its not useful to doctors, yet

leisure time

After Sarepta trial failure, Duchenne families brace for more debate

Kidney transplant patients stopped immunosuppressants in trial

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

It's time to retire 'poor historian' from clinicians' vocabularies

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Inari Medical to buy amputation prevention company LimFlow

hotspot

focus

entertainment

explore